Skip to content
TrialScanner

NCT04567550

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Phase 2CompletedABBVLeadRGNXCollaborator

Registry record

Lead sponsor
AbbVie
Conditions
Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME)
Primary completion
Jun 18, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04567550 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

2 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04567550: RGX-314 Gene Therapy... | TrialScanner